应用^(99)Tc^(m)-MIBI纳米粒子SPECT-CT显像评价乳腺癌对新辅助化疗的耐药性试验研究初探  

Preliminary study of SPECT-CT imaging with^(99)Tc^(m)-MIBI nanoparticles in evaluating the drug resistance of breast cancer to neoadjuvant chemotherapy

作　　者：李卫鹏 李辉 胡永全 陶新全 申勇 孙景秋 袁超 LI Weipeng;LI Hui;HU Yongquan;TAO Xinquan;SHEN Yong;SUN Jingqiu;YUAN Chao(Department of Nuclear Medicine,the First Affiliated Hospital of Bengbu Medical University,Bengbu,Anhui 233004,China)

机构地区：[1]蚌埠医科大学第一附属医院核医学科,安徽蚌埠233004

出　　处：《中华全科医学》2024年第5期764-767,780,共5页Chinese Journal of General Practice

基　　金：安徽省高校自然科学研究重点项目(2023AH052016);蚌埠医学院自然科学基金重点项目(2020byzd097)。

摘　　要：目的初步探讨应用^(99)Tc^(m)-MIBI纳米粒子SPECT-CT显像在评价乳腺癌对新辅助化疗的耐药性试验中的价值,旨在寻找一种预测新辅助化疗疗效的无创评价手段。方法制备^(99)Tc^(m)-MIBI纳米粒子显像剂;构建荷人乳腺癌裸鼠的模型;对裸鼠模型采用表柔比星联合多西他赛(ET)化疗:第1、2天表柔比星40 mg/(m^(2)·d),尾静脉给药;第3天多西他赛60 mg/m^(2),尾静脉给药,3周为1个周期,共化疗3个周期;化疗前后应用^(99)Tc^(m)-MIBI纳米粒子SPECT-CT显像,观察影像变化情况,通过ROI技术,计算每只乳腺癌裸鼠模型的肿瘤与周围本底的比值(T/B)。结果根据UICC实体瘤疗效评定标准进行评估人乳腺癌裸鼠的模型联合化疗后的疗效,在40只人乳腺癌裸鼠模型中,部分缓解(PR)27只,疾病稳定(SD)12只,疾病进展(PD)1只;人乳腺癌裸鼠模型化疗前行^(99)Tc^(m)-MIBI纳米粒子SPECT-CT显像的T/B为2.98±0.73,部分缓解组(PR)裸鼠模型化疗后行^(99)Tc^(m)-MIBI纳米粒子SPECT-CT显像的T/B为1.52±0.59,T/B值与化疗前比较差异有统计学意义(P<0.05);疾病稳定(SD)组裸鼠模型化疗后行^(99)Tc^(m)-MIBI纳米粒子SPECT-CT显像的T/B为3.12±1.09,与化疗前差异无统计学意义(P>0.05)。结论对于乳腺癌患者,有望采用^(99)Tc^(m)-MIBI纳米粒子SPECT-CT显像来评价对新辅助化疗药物的治疗效果,这是一种无创的评价乳腺癌对新辅助化疗耐药性的方法。Objective To explore the value of SPECT-CT imaging with^(99)Tc^(m)-MIBI nanoparticle in evaluating the drug resistance of breast cancer to neoadjuvant chemotherapy,to find a non-invasive evaluation method to predict the efficacy of neoadjuvant chemotherapy.Methods The imaging agent^(99)Tc^(m)-MIBI nanoparticle was prepared and the nude mouse model of carcinoma of breast was established.The nude mouse model was treated with combination chemotherapy of epirubicin and docetaxel(ET)as follows:on the 1st day,epirubicin 40 mg/(m·d)was administered via tail vein for two days,then on the 3rd day,docetaxel 60 mg/m^(2)was administered via tail vein,3 weeks per cycle,with a total of 3 cycles of chemotherapy.^(99)Tc^(m)-MIBI nanoparticles SPECT-CT imaging was used before and after chemotherapy to observe the image changes.The ratio of tumor to surrounding background(T/B)of each nude mouse model of breast cancer was calculated by ROI technology.Results According to UICC solid tumor efficacy evaluation criteria,the efficacy of combined chemotherapy in nude mice with human breast cancer was evaluated,In 40 nude mouse models of human breast cancer,27 partial remission(PR),12 disease stability(SD),and 1 disease progression(PD);The T/B of^(99)Tc^(m)-MIBI nanoparticles SPECT-CT imaging before chemotherapy in nude mouse model of human breast cancer was 2.98±0.73,The T/B value of^(99)Tc^(m)-MIBI nanoparticle SPECT-CT imaging after chemotherapy in the partially relieved(PR)nude mouse model was 1.52±0.59,and there was a significant difference in T/B value compared to before chemotherapy(P<0.05);The T/B of^(99)Tc^(m)-MIBI nanoparticle SPECT-CT imaging in the disease stable(SD)nude mouse model after chemotherapy was 3.12±1.09,and the difference was not significant compared to before chemotherapy(P>0.05).Conclusion For breast cancer patients,^(99)Tc^(m)-MIBI nanoparticles SPECT-CT imaging is expected to evaluate the therapeutic effect of neoadjuvant chemotherapy drugs,which is a non-invasive method to evaluate the drug resistance of b

关 键 词：^(99)Tc^(m)-MIBI SPECT-CT显像 乳腺癌 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤] R-332[医药卫生—临床医学]